Liver international : official journal of the International Association for the Study of the Liver · 2026
Epigenetic Regulation of MicroRNA Expression by Hepatitis B Virus Pre-S2 Mutant Promotes Hepatocellular Carcinoma Tumorigenesis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Yueh-Te, Jeng Long-Bin, Shih Fu-Ying, Teng Chiao-Fang
Аннотация
BACKGROUND & AIMS: Discovery of therapeutic targets for hepatocellular carcinoma (HCC) is urgently needed. As an important hepatitis B virus (HBV) oncoprotein, pre-S2 mutant activates multiple signalling pathways to induce HCC development.
METHODS: This study investigated the effect of pre-S2 mutant on regulating microRNA (miRNA) expression and the role of miRNAs in mediating pre-S2 mutant's oncogenic functions.
RESULTS: The results showed that 9 miRNAs were downregulated in both tumour tissues of pre-S2 mutant-positive HCC patients and pre-S2 mutant-expressed human HCC cell lines, contributing to pre-S2 mutant-promoted cell proliferation, anchorage-independent cell growth, cell cycle progression, and tumour growth and malignancy. Moreover, pre-S2 mutant downregulated miRNA expression at the epigenetic levels through suppression of lysine acetyltransferase 3B (KAT3B)- and KAT5-mediated histone H3 lysine 9 acetylation (H3K9ac) and H4K5ac modifications. The decreased levels of pre-S2 mutant-dysregulated miRNAs could also be detected in blood exosomes of patients.
CONCLUSIONS: Collectively, this study provided new mechanistic insights and therapeutic perspectives for pre-S2 mutant-associated HCC tumorigenesis.
METHODS: This study investigated the effect of pre-S2 mutant on regulating microRNA (miRNA) expression and the role of miRNAs in mediating pre-S2 mutant's oncogenic functions.
RESULTS: The results showed that 9 miRNAs were downregulated in both tumour tissues of pre-S2 mutant-positive HCC patients and pre-S2 mutant-expressed human HCC cell lines, contributing to pre-S2 mutant-promoted cell proliferation, anchorage-independent cell growth, cell cycle progression, and tumour growth and malignancy. Moreover, pre-S2 mutant downregulated miRNA expression at the epigenetic levels through suppression of lysine acetyltransferase 3B (KAT3B)- and KAT5-mediated histone H3 lysine 9 acetylation (H3K9ac) and H4K5ac modifications. The decreased levels of pre-S2 mutant-dysregulated miRNAs could also be detected in blood exosomes of patients.
CONCLUSIONS: Collectively, this study provided new mechanistic insights and therapeutic perspectives for pre-S2 mutant-associated HCC tumorigenesis.